SBIR-STTR Award

High Throughput Leukemia Diagnosis
Award last edited on: 8/25/03

Sponsored Program
SBIR
Awarding Agency
NIH : NCI
Total Award Amount
$98,688
Award Phase
1
Solicitation Topic Code
394
Principal Investigator
Jian Han

Company Information

Genaco Biomedical Products Inc

2707 Artie Street Building 100 Suite 20
Huntsville, AL 35805
   (256) 425-0051
   info@genaco.com
   www.genaco.com
Location: Single
Congr. District: 05
County: Madison

Phase I

Contract Number: 1R43CA103201-01
Start Date: 7/15/03    Completed: 5/31/04
Phase I year
2003
Phase I Amount
$98,688
Recurrent chromosome translocations in leukemias are useful cytogenetic markers for monitoring diagnosis, prognosis and treatment. Traditional cytogenetic study cannot recognize all the gene rearrangements at the molecular level. Also, it is a time consuming and labor intensive procedure. We have developed a proprietary technology that will allow high throughput screening and detection of multiple translocations at a time. The technology, ROCASH (for Reporter Oligo Capturing After Specific Hybridization), utilizes a labeled reporter oligo to study target nucleic acid in a two-step hybridization procedure. The advantages of this method are increased specificity and sensitivity. The end user will not need to perform labeling of the samples. Luminex xMAP technology is used as a platform for this procedure. It can investigate up do 50 genes in one assay. In this feasibility study, four common recurrent translocations will be studied. The long-term goal of this proposed project is to develop a user-friendly reagent kit that will allow the screening of all the genes involved in recurrent chromosome translocations. The kit will be usefuL in diagnosis, molecular classification of the leukemias, prognosis, and treatment monitoring.

Thesaurus Terms:
chromosome translocation, diagnosis design /evaluation, leukemia, neoplasm /cancer diagnosis, reagent /indicator, technology /technique development diagnosis quality /standard, gene expression, genetic screening, high throughput technology cell line, clinical research, polymerase chain reaction

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----